Who is sponsoring NCT00502203?

NCT00502203 is sponsored by M.D. Anderson Cancer Center.

What condition does NCT00502203 study?

NCT00502203 studies Mixed Tumor, Mullerian.

What drugs are being tested in NCT00502203?

Interventions: Carboplatin, Paclitaxel.

What is the status of NCT00502203?

NCT00502203 is currently COMPLETED.

Last reviewed 2016-04-05 · How we verify

A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

NCT00502203 Phase 2 COMPLETED Results posted

The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	COMPLETED
Enrolment	23
Start date	2001-08
Completion	2010-11

Conditions

Mixed Tumor, Mullerian

Interventions

Carboplatin
Paclitaxel

Primary outcomes

Number of Participants With Overall Response — 24 Months
Overall response rate including complete (CR) and partial responses (PR) with measurable disease using Response Evaluation Criteria In Solid Tumors (RECIST) assessment. CR: Disappearance of all target and non-target lesions; no evidence of new lesions documented by 2 disease assessments at least 4 weeks apart. PR: At least 30% decrease in sum of longest dimensions (LD) of all target measurable lesions reference baseline sum of LD; no unequivocal progression of non-target lesions and no new lesions. Documentation by 2 disease assessments at least 4 weeks apart is required.

Countries

United States